WASHINGTON (news agencies) — Federal health officials posted a warning Tuesday about misleading statements made by biotech billionaire Dr. Patrick Soon-Shiong, who recently told podcast listeners that his company’s bladder cancer drug may be able to treat, cure or even prevent other types of cancers.
The warning letter from the Food and Drug Administration takes issue with a TV advertisement and a separate podcast episode promoting Anktiva, the lead product of ImmunityBio Inc. The drugmaker is one of several biotech firms acquired by Soon-Shiong, who also owns the Los Angeles Times.
Company shares fell more than 21% in trading Tuesday to close at $7.42 after the FDA letter posted online.
Anktiva was approved by the FDA in 2024 for patients with a hard-to-treat form of bladder cancer. ImmunityBio has been working to win FDA approval to expand the drug’s use to a number of other conditions, including forms of lung and pancreatic cancer.
Soon-Shiong’s controversial statements came during a January episode of “The Sean Spicer Show” podcast titled “Is the FDA blocking life-saving cancer treatments?”
At one point during the interview, Soon-Shiong described his company’s drug as “the most important molecule that could cure cancer.” A few minutes later, Soon-Shiong — who is the company’s executive chairman and chief medical officer — said that while the drug is approved for bladder cancer, “it actually can treat all cancers.”
Later in the episode he said, “We have the therapy to prevent cancer if you were exposed to radiation, and that’s Anktiva.”
FDA regulators said the statements violate federal drug marketing rules because they “create a misleading impression” of the drug.
Regulators also noted that the podcast didn’t contain any information about risks and side effects of the drug, which can include urinary tract infections, pain, chills and pyrexia. Under FDA law, drug promotions are required to give a balanced view of a drug’s risks and benefits.
The FDA warning, addressed to ImmunityBio CEO Richard Adcock, raises similar concerns with a TV advertisement for Anktiva. Both the ad and the podcast refer to the company’s drug as a “cancer vaccine,” which the FDA said is false.
The letter gives the company 15 days to correct the problems and respond to the agency in writing about its plans to comply. By Tuesday afternoon, a link to the podcast had been removed from ImmunityBio’s website.
Sarah Singleton, spokesperson for Culver City, California-based ImmunityBio, said via email that the company takes the FDA’s warning “very seriously,” and plans to “work cooperatively with the agency to address the matters raised in the letter.”
Under the Trump administration, the FDA has stepped up warnings against drugmakers as well as online pharmacies, including appearances by company executives on TV shows and podcasts.
___
media Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The news agencies is solely responsible for all content.
